Market Access EMA’s strategy for speeding up drug approvals in the EU The EMA is implementing major changes to accelerate drug approvals in the EU, addressing delays that affect patients and businesses alike
Digital Power of digital technology and partnership to accelerate de... We are living through the fastest period of digital growth in human history. New technologies are transforming how we live, work, connect and innovate.
Sales & Marketing Balancing interests in launching medicines Launching new medicine at the right price is a complex issue, requiring a balance of interests
Market Access Innovative Medicines Fund and the opportunity for ICSs-indus... In June 2022, NHS England (NHSE) and the National Institute for Health and Care Excellence (NICE) launched the Innovative Medicines Fund (IMF).
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.